Format

Send to

Choose Destination
PLoS One. 2019 Feb 28;14(2):e0210854. doi: 10.1371/journal.pone.0210854. eCollection 2019.

Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model.

Author information

1
Department of Physical Education, College of Education, Daegu Catholic University, Gyeongsan, Republic of Korea.
2
Center for Vascular Research, Institute for Basic Science (IBS), Daejeon, Republic of Korea.
3
Research & Development Center, Korea BeRM Co. Ltd., Wonju, Republic of Korea.
4
Bien Co. Ltd., Sapporo, Japan.
5
Department of Food Science and Biotechnology, Dongguk University, Goyang, Republic of Korea.
6
Division of Food Bioscience, College of Biomedical and Health Sciences, Konkuk University, Chungju, Republic of Korea.
7
School of Bio-science and Food Engineering, Changchun University of Science and Technology, Changchun, China.
8
Department of Physical Education, Dong-Eui University, Busanjin-gu, Busan, Republic of Korea.
9
Institute for Natural Science Research, Hannam University, Daejeon, Republic of Korea.

Abstract

Recent studies have demonstrated the immunomodulatory effects of heat-killed lactic acid bacteria. The aim of this study was to evaluate the protective effect of heat-killed Enterococcus faecalis EF-2001 (EF-2001) on a model of inflammatory bowel disease (IBD). A total of 28 female NC/Nga mice were divided into 4 treatment groups. Controls were fed a normal commercial diet. In the experimental groups, colitis was induced by rectal administration of dinitrobenzene sulfonic acid. Two groups were orally administered 2 and 17 mg/kg EF-2001, respectively. EF-2001 treatment decreased the expression of several cytokines, including cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), interferon (IFN)-γ, interleukin (IL)-1β, and IL-6 in inflamed colon compared to the DNBS alone group. In addition, EF-2001 suppressed DNBS-induced colonic tissue destruction. Therefore, this study strongly suggests that EF-2001 could alleviate the inflammation associated with mouse IBD.

Conflict of interest statement

W Kim, K Han. M Iwasa, A Ogasawara are employed by commercial company Korea BeRM Co. Ltd., who provided ‘EF-2001’. K Kobayashi is employed by commercial company Bien Co. Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center